[1]Zhou J, Xiao X, Yi H, et al. Upregulation of Gp96 correlates with the radiosensitivity and five-year survival rate of nasopharyngeal carcinoma[J]. ORL J Otorhinolaryngol Relat Spec, 2012, 74(3):164-71. [2]Huang PY, Mai HQ, Luo DH, et al. Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma[J]. Ai Zheng, 2009, 28(10): 1033-42. [3]Bossi P, Orlandi E, Bergamini C, et al. Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locallyadvanced EBV-related nasopharyngeal cancer[J]. Ann Oncol, 2011, 22(11): 2495-500. [4]Zhang W, Yang HC, Wang Q, et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis[J]. Anticancer Res, 2011, 31(10): 3423-8. [5]Hiro J, Inoue Y, Toiyama Y, et al. Possibility of paclitaxel as an alternative radiosensitizer to 5-fluorouracil for colon cancer[J]. Oncol Rep, 2010, 24(4): 1029-34. [6]Mostafa E, Nasar MN, Rabie NA, et al. Induction chemotherapy with paclitaxel and cisplatin, followed by concomitant cisplatin and radiotherapy for the treatment of locally advanced nasopharyngeal carcinoma[J]. J Egypt Natl Canc Inst, 2006, 18(4): 348-56. [7]Phillips PG, Yalcin M, Cui H, et al. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novelnon-anticoagulant low molecular weight heparin[J]. Anticancer Res, 2011, 31(2): 411-9. [8]Dredge K, Hammond E, Handley P, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models[J]. Br J Cancer, 2011,104(4): 635-42. [9]Chen Y, Chen Y, Huang L, et al. Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma[J]. J Dermatol, 2012, 39(4): 339-43. [10]Kwong DL, Sham JS, Leung LH, et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngealcarcinoma[J]. Int J Radiat Oncol Biol Phys, 2006, 64(2): 374-81. [11]Ahmad S, Ansari AA. Therapeutic roles of heparin anticoagulantsin cancer and related disorders [J]. Med Chem, 2011, 7(5): 504-17. [12]Canales JF, Ferguson JJ. Low-molecular-weight heparins: mechan-isms, trials, and role in contemporary interventional medicine[J].Am J Cardiovasc Drugs, 2008, 8(1): 15-25. [13]Niers TM, Klerk CP, Dinisio M, et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models [J]. Crit Rev Oncol Hematol, 2007, 61(3): 195-207. [14]Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence[J]. Thromb Haemost, 2009,102(2): 258-67. [15]Pandita D, Ahuja A, Velpandian T, et al. Characterization andin vitroassessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique[J]. Pharmazie, 2009, 64(5): 301-10. [16]Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer[J]. JClin Oncol, 2009, 27(31): 5287-97. [17]Lan YY, Hsiao JR, Chang KC, et al. Epstein-Barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9[J]. J Virol, 2012, 86(12): 6656-67. [18]Groblewska M, Siewko M, Mroczko B, et al. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer[J]. Folia Histochem Cytobiol,2012, 50(1): 12-9. [19]Farina AR, Cappabianca L, Desantis G, et al. Thioredoxin stimul-ates MMP-9 expression, de-regulates the MMP-9/TIMP-1 equilibrUm and promotes MMP-9 dependent invasion in humanMDA-MB-231 breast cancer cells[J]. FEBS Lett, 2011, 585(20): 3328-36. [20]Teoh ML, Fitzgerald MP, Oberley LW, et al. Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion[J]. Cancer Res, 2009, 69(15): 6355-63. [21]Ilan N, Elkin M, Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis [J]. Int J Biochem Cell Biol, 2006, 38(12): 2018-39. [22]Raman K, Kuberan B. Chemical tumor biology of heparan sulfate proteoglycans[J]. Curr Chem Biol, 2010, 4(1): 20-31. |